e-vive, from CyMedica Orthopedics, is designed to deliver wireless, app-controlled muscle stimulation therapy individualized for each patient’s comfort and convenience. (Photo courtesy of CyMedica Orthopedics)
CyMedica Orthopedics announces that the first patient has been enrolled in a clinical trial evaluating its e-vive neuromuscular activation/engagement system for postoperative total knee arthroplasty rehabilitation.
“This clinical trial will allow us to accelerate what we believe is an essential shift in the care model for total knee postsurgical rehabilitation,” says Rob Morocco, president and CEO of Scottsdale, Ariz-based CyMedica.
The e-vive system is designed to address the problems associated with strength-induced muscle atrophy where patients can lose significant quadriceps strength after knee surgery.
Such atrophy can also incur additional post-acute care costs due to additional rehabilitation as well as a higher likelihood of hospital readmissions, according to the company, in a media release.
“As bundled programs and the healthcare models evolve, orthopedic surgeons will continue to be advocates for better postsurgical rehabilitation innovations that engage patients in their care and provide more efficient ways to provide these services,” explains Carlos Higuera-Rueda, MD, orthopedic surgeon at Cleveland Clinic and the clinical trial’s primary investigator
“At Cleveland Clinic, we are constantly looking for options that allow doctors and their rehabilitation partners to put patients first. The goal of this research is to help the orthopedic and physical therapy communities give better care,” he states, per the release.
[Source(s): CyMedica Orthopedics, PR Newswire]
